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Abstract 
BACKGROUND: This study aimed to evaluate the roles of erythropoietin-producing 
hepatocellular carcinoma (Eph)/Eph receptor–interaction protein (Ephrin) molecules in 
ameloblastomas by immunohistochemically analyzing their expression in odontogenic 
tissues. 
METHODS: Tissue specimens from 8 dental follicles and 64 ameloblastomas were 
immunohistochemically examined with antibodies against EphA2, EphB4, Ephrin-B2, 
CD34, and D2-40. 
RESULTS: Immunohistochemical reactivity for EphA2, EphB4, and Ephrin-B2 was 
detected in odontogenic epithelial cells and several vessels in dental follicles and 
ameloblastomas. EphA2, EphB4, and Ephrin-B2 reactivity in ameloblastomas was 
significantly higher than that in dental follicles. Microvessel density (MVD) and 
lymphatic vessel density (LVD) in primary ameloblastomas were significantly higher 
than those in dental follicles. The MVD in solid ameloblastomas was significantly higher 
than that in unicystic ameloblastomas. 
CONCLUSION: EphA2, EphB4, and Ephrin-B2 expression in dental follicles and 
ameloblastomas might be associated with tumor development and growth with specific 
cell differentiation and tissue structuring via angiogenesis and lymphangiogenesis in the 
intraosseous microenvironment. 
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Introduction 
Ameloblastoma is the most common epithelial odontogenic tumor; it mainly occurs in the 
mandible and is characterized by benign but locally invasive behavior accompanied by a 
high recurrence rate. Therefore, clinical long-term follow-up is essential, and the required 
treatment is wide surgical excision, including an adequate margin of uninvolved tissues, 
similar to that for malignant tumors.1  
This tumor is usually solid/multicystic or unicystic. Histologically, solid/multicystic 
ameloblastoma shows two basic patterns—follicular and plexiform—and often includes 
cellular variations, such as acanthomatous, granular, basaloid, and desmoplastic 
ameloblastomas. The 2017 World Health Organization (WHO) classification divides 
unicystic ameloblastoma into luminal and intraluminal variants. The mural type that was 
classified as the unicystic type in the 2005 WHO Classification has now been included in 
conventional ameloblastoma.1,2 Recent studies have identified genetic and molecular 
alterations in epithelial odontogenic tumors, such as BRAF mutations; however, detailed 
information regarding oncogenesis, cytodifferentiation, and tumor progression is not 
available.3 
The tumor microenvironment is composed of various stromal components, including 
blood vessels, lymphatic vessels, fibroblasts, and inflammatory cells that exhibit different 
regulatory functions during tumor growth. In addition, the angiogenesis and 
lymphangiogenesis noted in malignancies correlate with local tumor growth, regional 
lymph node metastasis, and systemic dissemination.4,5 Immunohistochemical expression 
of CD34, CD105 (endoglin), and D2-40 (podoplanin) has been reported in the tooth germ, 
ameloblastoma, and ameloblastic carcinoma.6 
The erythropoietin-producing hepatocellular carcinoma (Eph) family is one of the 
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receptor tyrosine kinases to which their ligand Eph receptor interaction protein (Ephrin) 
binds via direct cell–cell interactions. The Eph family molecules consist of two 
subclasses—EphA1-10 and EphB1-6—which are grouped according to their sequence 
conservation and binding affinity for distinct types of Ephrin ligands, including Ephrin-
A1–A5 and Ephrin-B1–B3.7,8 Eph/Ephrin signaling plays a role in cell locomotion and 
boundary formation in the development of many tissues and in tumorigenesis.7-9 Previous 
studies reported Ephrin-A1–A5, EphA2–A4, EphA7, and EphA8 mRNA expression in 
the embryonic mandibular first molar tooth germ in mice, and Ephrin-B1–EphB2 
interaction was found to regulate odontogenic/osteogenic differentiation from dental pulp 
cells in vitro.10,11 Specific overexpression of EphA2, EphB4, and Ephrin-B2 is correlated 
with advanced tumor growth, metastasis, and poor prognosis of common human 
carcinomas, such as head and neck, thyroid, breast, and colorectal carcinomas.12-15 
In the current study, the effects of the Eph/Ephrin system on oncogenesis, 
cytodifferentiation, angiogenesis, lymphatic angiogenesis, and outcome of epithelial 
odontogenic tumors were studied. For this analysis, we studied and compared the 
following in ameloblastomas and dental follicles: immunohistochemical expression of 
EphA2, EphB4, and Ephrin-B2; microvessel density (MVD); and lymphatic vessel 
density (LVD). 
 
Materials and Methods 
The study protocol was independently reviewed and approved by the Research Ethics 
Committee of the Tohoku University Graduate School of Dentistry (2018-3-9). 
 
Tissue preparation 
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Specimens were surgically removed from 64 patients with ameloblastomas at Tohoku 
University Hospitals. The specimens were fixed in 10% buffered formalin for one to 
several days and were embedded in paraffin. The tissue blocks were sliced into 3-µm-
thick sections for routine histological examination and subsequent immunohistochemical 
analysis. Tissue sections were stained with hematoxylin and eosin for histological 
diagnosis performed according to the WHO histological classification of odontogenic 
tumors.1  
The specimens consisted of 45 primary ameloblastomas and 19 recurrent 
ameloblastomas. Of the primary ameloblastomas, 36 were solid, and 9 were unicystic. 
The solid ameloblastomas comprised 19 follicular and 17 plexiform type ameloblastomas, 
which included 12 and 3 specimens belonging to the acanthomatous and granular cell 
subtypes, respectively. The unicystic ameloblastomas were divided into three luminal, 
three intraluminal, and three mural type ameloblastomas. The unicystic ameloblastoma 
subtypes were classified as per the WHO classification of 2005.2 All recurrent 
ameloblastomas were solid and were divided into 13 follicular and 6 plexiform type 
ameloblastomas, including 10 and 1 specimens belonging to the acanthomatous and 
granular cell subtypes, respectively. Specimens from eight dental follicles of the 
mandibular third molars were similarly prepared and compared with ameloblastomas. 
 
Immunohistochemistry for EphA2, EphB4, Ephrin-B2, CD34, and D2-40 expression 
Tissue sections were deparaffinized and immersed in methanol with 0.3% hydrogen 
peroxide. Sections for EphA2, EphB4, and Ephrin-B2 analysis were heated in 0.01 M 
citrate buffer (pH 6.0) for 10 min by autoclaving (121°C, 2 atm). The sections were 
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incubated with primary antibodies at 4°C overnight. The following antibodies were used: 
rabbit anti-EphA2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA; 1:50 dilution); rabbit anti-EphB4 polyclonal antibody (Proteintech, Rosemont, IL, 
USA; 1:100 dilution); rabbit anti-Ephrin-B2 polyclonal antibody (Santa Cruz 
Biotechnology; 1:50 dilution); mouse anti-CD34 monoclonal antibody (Nichirei, Tokyo, 
Japan; subclass IgG1; prediluted); and mouse anti-D2-40 monoclonal antibody 
(Biolegend, San Diego, CA, USA; subclass IgG1; prediluted). The sections were allowed 
to react with peroxidase-conjugated anti-rabbit or mouse IgG polyclonal antibody 
(Histofine Simple Stain MAX-PO; Nichirei) for 45 min, and the reaction products were 
visualized by immersing the sections in 0.03% diaminobenzidine (DAB) solution 
containing 2 mM hydrogen peroxide for 3–5 min. Nuclei were lightly stained with 
Mayer’s hematoxylin.  
For control studies of the antibodies, serial tissue sections were treated with phosphate-
buffered saline (PBS), normal rabbit IgG, and mouse anti-LCA monoclonal antibody 
(Nichirei; subclass IgG1) instead of primary antibodies was confirmed to be unstained. 
 
Immunostaining analysis  
Immunohistochemical reactivity for EphA2, EphB4, and Ephrin-B2 was evaluated and 
classified into four groups: -, negative; ±, weakly positive in less than 50% of epithelial 
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or neoplastic cells; +, weakly positive in more than 50% of epithelial or neoplastic cells; 
and ++, moderately to strongly positive in more than 50% of epithelial or neoplastic cells. 
On the basis of the criteria of Li et al.14 
MVD and LVD were estimated by analyzing CD34-positive blood vessel endothelial 
cells and D2-40-positive lymphatic endothelial cells. After scanning five areas showing 
the highest neovascularization (vascular hotspots) in normal mesenchymal tissues or 
tumor stromal tissues at 20-fold magnification, CD34-positive vessels and D2-40-positive 
lymphatic vessels in the hotspots were counted at 200-fold magnification, and the average 
count was recorded as MVD and LVD for each case. On the basis of the criteria of 
Weidner et al, highlighted endothelial cells or endothelial cell clusters that were clearly 
separate from the adjacent vessels, epithelial cells, and other connective tissue elements 
were regarded as distinct countable vessels.16 The presence of a lumen or blood cells was 
not required, and single cell sprouts were included in the counts. 
  
Statistical analysis  
The statistical significance of differences in percentages of cases with different reactivity 
levels was analyzed by the Mann-Whitney U-test for differences between two groups or 
the Kruskal-Wallis test for differences among three or more groups. P-values less than 
0.05 were considered to indicate statistical significance. 
 
Results 
The results of immunohistochemical analyses of EphA2, EphB4, and Ephrin-B2 
expression and MVD and LVD in dental follicles and ameloblastomas are summarized in 
Tables 1 and 2. Immunohistochemical reactivity for EphA2, EphB4, and Ephrin-B2 was 
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detected in the cytoplasm of odontogenic epithelial cells and vascular endothelial cells in 
dental follicles (Figures 1A, 2A, 3A) and ameloblastomas (Figures 1B-F, 2B-F, 3B-F). 
The dental lamina showed EphA2 reactivity in three of eight dental follicles (Figure 
1A). In primary ameloblastomas, neoplastic cells showed EphA2 reactivity in 42 of 45 
cases, including 34 of 36 solid ameloblastomas and 8 of 9 unicystic ameloblastomas 
(Figure 1B-F). EphA2 expression in ameloblastomas was significantly higher than that in 
dental follicles (P < 0.001). Solid ameloblastomas showed EphA2 expression in 18 of 19 
follicular and 16 of 17 plexiform ameloblastomas (Figure 1B, C). Increased EphA2 
reactivity was often found in keratinizing cells of acanthomatous ameloblastomas (Figure 
1D). Granular cells of granular cell ameloblastomas were reactive with EphA2 (Figure 
1E). Neoplastic cells in unicystic ameloblastomas showed EphA2 reactivity in all three 
luminal, two of three intraluminal, and all three mural type ameloblastomas (Figure 1F). 
EphA2 reactivity was noted in 18 of 19 recurrent ameloblastomas. 
The dental lamina showed no or weak EphB4 reactivity in dental follicles (Figure 2A), 
while neoplastic cells in primary ameloblastomas were positive in 44 of 45 cases, 
including 35 of 36 solid ameloblastomas and all 9 unicystic ameloblastomas (Figure 2B-
F). EphB4 expression in ameloblastomas was significantly higher than that in dental 
follicles (P < 0.001). The solid ameloblastomas showed EphB4 reactivity in 18 of 19 
follicular and all 17 plexiform ameloblastomas, except for 1 acanthomatous 
ameloblastoma (Figure 2B-E). Follicular ameloblastomas showed EphB4 reactivity in 
many peripheral columnar cells and some central polyhedral cells (Figure 2B), and 
plexiform ameloblastomas showed EphB4 reactivity in most neoplastic cells (Figure 2C). 
Keratinizing cells in acanthomatous ameloblastomas did not show EphB4 reactivity 
(Figure 2D), whereas granular cells in granular cell ameloblastomas were reactive with 
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EphB4 (Figure 2E). Neoplastic cells in unicystic ameloblastomas showed EphB4 
reactivity in all three luminal, all three intraluminal, and all three mural type 
ameloblastomas (Figure 2F). EphB4 reactivity was noted in all 19 recurrent 
ameloblastomas. 
The dental lamina showed Ephrin-B2 reactivity in two of eight dental follicles (Figure 
3A). In primary ameloblastomas, neoplastic cells showed Ephrin-B2 reactivity in 38 of 
45 cases, including 29 of 36 solid ameloblastomas and all 9 unicystic ameloblastomas 
(Figure 3B-F). Ephrin-B2 expression in ameloblastomas was significantly higher than 
that in dental follicles (P < 0.001). Solid ameloblastomas showed EphA2 expression in 
17 of 19 follicular and 12 of 17 plexiform ameloblastomas (Figure 3B, C). Keratinizing 
cells in acanthomatous ameloblastomas were not reactive with Ephrin-B2 (Figure 3D), 
whereas granular cells in granular cell ameloblastomas were reactive with Ephrin-B2 
(Figure 3E). Neoplastic cells in unicystic ameloblastomas showed Ephrin-B2 expression 
in all three luminal, all three intraluminal, and all three mural type ameloblastomas 
(Figure 2F). Ephrin-B2 reactivity was noted in 16 of 19 recurrent ameloblastomas. 
Immunohistochemical reactivity for CD34 was detected in the cytoplasm of vascular 
endothelial cells in both normal and neoplastic odontogenic tissues (Figure 4A-D). 
Positive staining for CD34 was found in microvessels near the dental lamina (Figure 4A). 
In ameloblastomas, CD34-positive microvessels were observed in the tumor stroma 
(Figure 4B-D). The MVD in ameloblastomas was significantly higher than that in dental 
follicles (P < 0.05). Follicular and plexiform ameloblastomas showed CD34 reactivity in 
many small vessels (Figure 4B, C); CD34-positive vessels in plexiform ameloblastomas 
were often dilated (Figure 4C). The MVD in solid ameloblastomas was significantly 
higher than that in unicystic ameloblastomas (P < 0.05). 
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Immunohistochemical expression of D2-40 was detected in the cytoplasm of lymphatic 
endothelial cells and odontogenic epithelial cells near the basement membrane in normal 
and neoplastic odontogenic tissues (Figure 5A-D). Dental follicles showed D2-40 
reactivity in a few small lymphatic vessels in connective tissues, while ameloblastomas 
showed D2-40 reactivity in scattered small lymphatic vessels in stromal tissues (Figure 
5B-D). The LVD in ameloblastomas was significantly higher than that in dental follicles 
(P < 0.05). 
 
Discussion 
Eph/Ephrin expression is widely distributed in various organs and contributes to their 
tissue development and tumorigenesis.7-9,12-15 During tooth development, EphA2 
expression has been detected at the tip of the dental epithelium at the bud stage, and, 
subsequently, around the primary enamel knot, which is located in the middle part of the 
tooth germ at the cap stage. EphA2 expression in the tooth germ has shown its ability to 
regulate tooth organogenesis.10 Some previous studies reported that the interaction of 
EphB and Ephrin-B signaling controls odontogenic/osteogenic differentiation in dental 
pulp stem cells (DPSCs).11,17 Protein and mRNA levels of Ephrin-B2, EphB2, and EphB4 
were found to be upregulated in DPSCs over 21 days of odontogenic/osteogenic induction 
during induction culture.17 In the current study, the effects of the Eph/Ephrin system on 
oncogenesis, cytodifferentiation, angiogenesis, lymphatic angiogenesis, and outcome of 
epithelial odontogenic tumors were studied using ameloblastoma and dental follicle 
specimens. EphA2, EphB4, and Ephrin-B2 expression was detected in the dental lamina 
and some vascular vessels, suggesting these molecules play a role in tooth development. 
Previous studies showed that EphA2 is overexpressed in tongue, salivary gland, 
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esophageal, and colorectal cancers and that EphB4 and Ephrin-B2 overexpression is 
correlated with lymph node metastases and poor survival in thyroid, breast, and colorectal 
cancers.12-15,18 Recently, EphB4 antibody has been reported to show underscoring the 
value for tumor imaging in mice xenografted with human breast and colorectal cancer 
cells.19 In the current study, EphA2, EphB4, and Ephrin-B2 reactivity was detected in 
odontogenic epithelial cells and some vascular endothelial cells in ameloblastomas. Their 
expression in ameloblastomas was significantly higher than that in dental follicles, 
suggesting that these Eph/Ephrin molecules are involved in oncogenesis in the 
odontogenic epithelium. Solid ameloblastomas tended to have higher EphA2 expression 
than unicystic ameloblastomas, and follicular ameloblastomas exhibited slightly higher 
EphA2 expression than plexiform ameloblastomas. Acanthomatous ameloblastomas and 
granular cell ameloblastomas tended to have higher EphA2 expression than noncellular 
ameloblastomas; increased EphA2 expression was also found in keratinizing cells of 
acanthomatous ameloblastomas. Intraluminal unicystic ameloblastomas tended to have 
lower EphA2 and Ephrin-B2 reactivity than luminal and mural type unicystic 
ameloblastomas. These features indicate that EphA2 and Ephrin-B2 signaling plays a role 
in cell differentiation and tissue structuring in ameloblastomas. Several studies have been 
performed on the role of EphA2 and EphB4 expression in recurrence in tongue, colorectal, 
and breast cancers, which suggest that these molecules could provide targets to improve 
cancer prevention.12,20-22 However, in our study, primary and recurrent ameloblastomas 
did not show apparent differences with respect to EphA2, EphB4, and Ephrin-B2 
expression and MVD and LVD. 
Angiogenesis is the formation of new blood vessels from existing vessels and plays an 
important role in tumorigenesis. Angiogenesis in small dormant tumors secreting factors 
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that induce the germination and chemotaxis of endothelial cells, leading to tumor mass.23 
In previous studies, EphA2 expression and increased MVD have been detected in 
hepatocellular carcinoma, and correlation among EphA2, vascular endothelial growth 
factor (VEGF), and MVD has been described in oral squamous cell carcinoma.12,24 In our 
previous study, VEGF expression and increased MVD were detected in ameloblastic 
tumors, suggesting that VEGF production by odontogenic epithelial cells and its related 
angiogenesis were associated with the pathophysiology of the neoplastic lesions.25 In the 
current study, CD34-based immunohistochemical evaluation of MVD showed that 
primary ameloblastomas had significantly higher MVD than dental follicles did. 
Furthermore, MVD was significantly higher in solid ameloblastomas than in unicystic 
ameloblastomas. These findings suggest that angiogenesis plays an important role in 
tumor development and tissue structuring of ameloblastomas. Since these results were 
associated with Eph/Ephrin expression, these molecules might play a role in angiogenesis 
in odontogenic tissue. 
VEGF-C/D, VEGF isoforms, and their receptor, VEGFR-3, a VEGF receptor subtype, 
play an important role in the neogenesis and development of lymphatic vessels.26 
Eph/Ephrin molecules were found to be related with angiogenesis and lymphangiogenesis 
in tissue development and lesion formation. Recently, it was found that anti-Ephrin-B2 
causes marked lymphatic defects in neonatal mice and that the agonist anti-EphB4 
negates the effect of Ephrin-B2 blockade, indicating the functional importance of EphB4 
in lymphangiogenesis.27 Previous immunohistochemical studies have reported D2-40 
expression in lymphatic vessels and the basal and suprabasal layers of odontogenic 
epithelial cells in the tooth germ and odontogenic lesions, including radicular cysts, 
odontogenic keratocysts, and ameloblastomas.28-30 In the current study, 
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immunohistochemical reactivity for D2-40 was detected in the lymphatic endothelial cells 
and odontogenic epithelium near the basement membrane in normal and neoplastic 
odontogenic tissues, although LVD was much lesser than MVD, suggesting that these 
cells are involved in increased adhesion, migration, elongated cell extension, and tube 
formation in lymphatic endothelial cells.28 We found that primary ameloblastomas 
showed significantly higher LVD than dental follicles, similar to the findings for MVD. 
In addition, follicular ameloblastomas tended to show higher LVD than plexiform 
ameloblastomas, and the luminal type tended to show lower LVD than intraluminal and 
mural types. These results suggest that tumor formation or the tissue architecture of 
odontogenic tissues is affected by lymphangiogenesis via Eph/Ephrin molecules. 
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Figure legends 
Figure 1. Immunohistochemical reactivity for EphA2. (A) Dental follicle showing no 
reactivity (magnification, ×200). (B, C) Follicular and plexiform ameloblastomas 
showing reactivity in most neoplastic cells (magnification, ×200). (D) Acanthomatous 
ameloblastoma showing reactivity in most neoplastic cells, with increased reactivity in 
keratinizing cells (magnification, ×200). (E) Granular cell ameloblastoma showing 
reactivity in most neoplastic cells, including granular cells (magnification, ×200). (F) 
Unicystic ameloblastoma (luminal type) showing reactivity in ameloblastomatous 
epithelium lining (magnification, ×200). 
Figure 2. Immunohistochemical reactivity for EphB4. (A) Dental follicle showing 
reactivity in the dental lamina (magnification, ×200). (B) Follicular ameloblastoma 
showing strong reactivity in most peripheral columnar cells and some reactivity in central 
polyhedral cells (magnification, ×200). (C) Plexiform ameloblastoma showing reactivity 
in most neoplastic cells (magnification, ×200). (D) Acanthomatous ameloblastoma 
showing reactivity in most neoplastic cells, except for keratinizing cells (magnification, 
×200). (E) Granular cell ameloblastoma showing reactivity in most neoplastic cells, 
including granular cells (magnification, ×200). (F) Unicystic ameloblastoma (mural type) 
showing reactivity in ameloblastomatous epithelium lining and infiltrating the cyst wall 
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(magnification, ×200). 
Figure 3. Immunohistochemical reactivity for Ephrin-B2. (A) Dental follicle showing no 
reactivity (magnification, ×200). (B, C) Follicular and plexiform ameloblastoma showing 
reactivity in most neoplastic cells (magnification, ×200). (D) Acanthomatous 
ameloblastoma showing reactivity in most neoplastic cells, except for keratinizing cells 
(magnification, ×200). (E) Granular cell ameloblastoma showing reactivity in most 
neoplastic cells, including granular cells (magnification, ×200). (F) Unicystic 
ameloblastoma (luminal type) showing reactivity in ameloblastomatous epithelium lining 
(magnification, ×200). 
Figure 4. Immunohistochemical reactivity for CD34. (A) Dental follicle showing 
reactivity in microvessels in the connective tissue (magnification, ×200). (B) Follicular 
ameloblastoma showing reactivity in small vessels in the tumor stroma (magnification, 
×200). (C) Plexiform ameloblastoma showing reactivity in dilated vessels in the tumor 
stroma (×200). (D) Unicystic ameloblastoma (luminal type) showing reactivity in small 
vessels in the tumor stroma (magnification, ×200). 
Figure 5. Immunohistochemical reactivity for D2-40. (A) Dental follicle showing 
reactivity in small lymphatic endothelial cells in the connective tissue (magnification, 
×200). (B, C) Follicular and plexiform ameloblastoma showing reactivity in small 
lymphatic endothelial cells and neoplastic cells near the basement membrane 
(magnification, ×200). (D) Unicystic ameloblastoma (intraluminal type) showing 
reactivity in small lymphatic endothelial cells and neoplastic cells near the basement 
membrane (magnification, ×200). 
 
Table１
Table1  Immunohistochemical reactivity for EphA2, EphB4, and EphrinB2 as well as  MVD and LVD in dental follicles and ameloblastomas
MVD LVD
n - ± + ++ - ± + ++ - ± + ++ (vessels / 200-fold field) (lymphatic vessels / 200-fold field)
Dental follicle 8 5 3 0 0 1 7 0 0 6 2 0 0 35.10±14.31 0.68±0.87
(6) (4) (0) (0) (1) (9) (0) (0) (7) (3) (0) (0)
Ameloblastoma 45 3 4 11 27 1 0 3 41 7 2 14 22 46.28±16.01 2.21±1.80
(7) (8) (24) (60) (2) (0) (7) (91) (16) (4) (31) (49)
  Solid ameloblastoma 36 2 4 7 23 1 0 3 32 7 1 10 18 49.08±14.57 2.19±1.71
(6) (11) (19) (64) (3) (0) (8) (89) (19) (3) (28) (50)
    Follicular type 19 1 0 2 16 1 0 0 18 2 0 6 11 46.74±13.78 2.63±2.20
(5) (0) (11) (84) (5) (0) (0) (95) (10) (0) (32) (58)
    Plexiform type 17 1 4 5 7 0 0 3 14 5 1 4 7 51.69±15.39 1.71±0.67
(6) (24) (29) (41) (0) (0) (18) (82) (29) (6) (24) (41)
      Non-cellular variation 21 1 3 7 10 0 0 3 18 5 1 5 10 51.86±15.97 1.81±0.93
(5) (14) (33) (48) (0) (0) (14) (86) (24) (4) (24) (48)
      Acanthomatous subtype 12 1 1 0 10 1 0 0 11 1 0 5 6 46.07±11.38 2.82±2.57
(8) (8) (0) (84) (8) (0) (0) (92) (8) (0) (42) (50)
      Granular cell subtype 3 0 0 0 3 0 0 0 3 1 0 0 2 41.67±13.93 2.40±1.40
(0) (0) (0) (100) (0) (0) (0) (100) (33) (0) (0) (67)
  Unicystic ameloblastoma 9 1 0 4 4 0 0 0 9 0 1 4 4 35.11±17.46 2.29±2.25
(12) (0) (44) (44) (0) (0) (0) (100) (0) (12) (44) (44)
    Luminal type 3 0 0 1 2 0 0 0 3 0 0 1 2 29.47±19.38 1.60±0.69
(0) (0) (33) (67) (0) (0) (0) (100) (0) (0) (67) (33)
    Intraluminal type 3 1 0 2 0 0 0 0 3 0 1 2 0 38.07±14.89 3.07±4.16
(33) (0) (67) (0) (0) (0) (0) (100) (0) (33) (67) (0)
    Mural type 3 0 0 1 2 0 0 0 3 0 0 1 2 37.80±23.46 2.20±0.87
(0) (0) (33) (67) (0) (0) (0) (100) (0) (0) (33) (67)
EphA2 EphB4 EphrinB2
EphA2, EphB4, and EphrinB2 expression: (-) negative in epithelial or tumor cells, (±) weakly positive in less than 50% of epithelial or neoplastic cells, (+) weakly positive in more than 50% of epithelial or neoplasitc cells, (++) moderately to strongly positive in more than 50% of
epithelial or neoplastic cells.
Values in parentheses denote percentage values.
MVD: microvessel density.
LVD: lymphatic vessel density.
Statistical significance: *P  <0.05, ***P  < 0.001
*** *** *** *
*
*
Table2  Immunohistochemical reactivity for EphA2, EphB4, and Ephrin B2 as well as MVD and LVD in primary and recurrent solid ameloblastomas
MVD LVD
n - ± + ++ - ± + ++ - ± + ++ (vessels / 200-fold field) (lymphatic vessels / 200-fold field)
Primary 36 2 4 7 23 1 0 3 32 7 1 10 18 49.08±14.57 2.19±1.71
(6) (11) (19) (64) (3) (0) (8) (89) (19) (3) (28) (50)
Recurrent 19 1 0 8 10 0 1 2 16 3 1 8 7 50.56±20.27 2.28±1.41
(5) (0) (42) (53) (0) (5) (11) (84) (16) (5) (42) (37)
EphA2 EphB4 EphrinB2
EphA2, EphB4, and EphrinB2 expression: (-) negative in epithelial or tumor cells, (±) weakly positive in less than 50% of epithelial or neoplastic cells, (+) weakly positive in more than 50% of epithelial or neoplasitc cells, (++) moderately to strongly positive
in more than 50% of epithelial or neoplastic cells.
Values in parentheses denote percentage values.
MVD: microvessel density.
LVD: lymphatic vessel density.
*
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